Calquence(Acalabrutinib)
AZN
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by AstraZeneca PLC
$564K
Medicare cost, 2024
$564K
Medicare cost, 2024
Medicare drug plans spent $564,130 on Calquence (acalabrutinib) in 2024, for 41 prescriptions and refills filled by 18 patients. Spending fell 99% from 2023 to 2024. At about $13,759 per prescription it is a high-cost drug. It is made by AstraZeneca PLC (AZN).
Medicare cost, 2024
$564K
-99.1% from 2023
Prescriptions
41
$13,759.27 per claim
Patients
18
16 prescribers
Total spending, 2024
$564K
$31,340.57 per patient
Questions and answers
How much does Medicare spend on Calquence?
Medicare prescription drug plans paid $564K for Calquence in 2024, for 41 prescriptions and refills to 18 patients (down 99.1% from 2023). The average cost per claim was $13,759.27.
Which state spends the most on Calquence?
Florida had the highest Medicare cost for Calquence in 2024: $185K for 13 claims, followed by Maryland ($160K).
Who prescribes Calquence the most?
Vinicio Hernandez, medical oncology in Orlando, FL, had the highest Medicare cost for Calquence in 2024: 13 claims costing $185K.
Who makes Calquence?
Calquence is made by AstraZeneca PLC (AZN), listed in the Medicare spending data as Astrazeneca.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Calquence was $564K in 2024, after a high of $1.03B in 2022.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Calquence, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Vinicio Hernandez Orlando, FL | Medical Oncology | 13 | Under 11 | $185K |
| Kavita B Kalra Baltimore, MD | Hematology-Oncology | 12 | Under 11 | $160K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 6,391 | 73,907 | 11,179 | $1.03B |
| 2023 | 1,755 | 4,264 | 2,589 | $59.7M |
| 2024 | 16 | 41 | 18 | $564K |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Astrazeneca | 41 | $564K |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 3
- RxNorm concept IDs
- 1986813, 1986819, 2607734, 2607737
- Application numbers
- NDA210259, NDA216387
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 12,744 side-effect reports named acalabrutinib, the active ingredient of Calquence (reports from 2016 on). 10,675 of them (83.8%) were serious, 2,699 named a death and 3,481 named a hospital stay. The reactions named most often were death, fatigue and headache. 10,640 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
12,744
2,330 in 2025 (-14.3% from 2024)
Serious
83.8%
10,675 reports
Deaths named
2,699
21.2% of reports
Hospital stays
3,481
27.3% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Calquence?
12,744 reports from 2016 through September 2026 named acalabrutinib, the active ingredient of Calquence. 10,675 of them (83.8%) were serious, 2,699 named a death and 3,481 named a hospital stay.
What are the most reported side effects of Calquence?
2,186 reports named death, the reaction named most often, followed by fatigue (725) and headache (657). In the last 5 years the reaction named most often was death (1,631 reports). A report can name several reactions.
How many side-effect reports named Calquence in 2025?
2,330 reports were received in 2025 (-14.3% from 2024). 2026 so far: 1,908 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Calquence caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Calquence caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Makers on the stock market:
AZN·AZN drug pipeline - Drug approvals (1 approval on file for acalabrutinib) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (acalabrutinib) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.